Introduction to the Albumin & Creatinine Tests Market
The
Albumin & Creatinine Tests Market measures the amount of albumin and
creatinine in the urine. Albumin is a protein produced by the liver, and
creatinine is a by-product of muscular activity. Both substances can be indicators
of kidney health, as well as other conditions such as diabetes, hypertension,
and cardiovascular disease. Albumin & Creatinine Tests are used to diagnose
and monitor kidney diseases and other conditions.
The
growing prevalence of chronic kidney diseases and the increasing number of
geriatric population across the world are the major factors driving the growth
of the market. Moreover, the emergence of innovative technologies in the field
of medical diagnostics is expected to further fuel the growth of the market.
Global
Albumin & Creatinine Tests Market Overview
The global albumin & creatinine tests market in
terms of revenue was estimated to be worth $987 million in 2020 and is poised
to reach $2,103 million by 2025, growing at a CAGR of 16.3% from 2020 to 2025.
Albumin & creatinine
are two common urinary proteins that are used to assess kidney function. Albumin
& creatinine tests are used to detect and diagnose diseases related to the
kidneys, such as nephritis, chronic kidney disease, and acute kidney injury.
The increasing prevalence of chronic kidney diseases, increasing geriatric
population, rising awareness regarding preventive healthcare, and the
increasing number of diagnostic centers across the globe are the major factors
driving the growth of the market. However, the high cost of albumin &
creatinine tests and the lack of awareness about the tests in developing
countries are the major factors restraining the growth of the market.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=156696568
Drivers
of the Albumin & Creatinine Tests Market
·
Increasing
prevalence of chronic diseases: The prevalence of chronic diseases such as
diabetes, kidney diseases, and liver diseases is rising across the globe. This
is expected to drive the demand for the albumin & creatinine tests market.
·
Growing
demand for early diagnosis: Early diagnosis of kidney diseases is critical for
successful treatment and improved outcome. The demand for albumin &
creatinine tests is expected to grow due to the increasing need for early
diagnosis of kidney diseases.
·
Technological
advancements: Technological advancements have enabled the development of
advanced tests that provide accurate and reliable results. This is expected to
drive the demand for albumin & creatinine tests.
·
Growing
geriatric population: The geriatric population is more prone to chronic
diseases. This is expected to drive the demand for the albumin & creatinine
tests market.
·
Increasing
awareness of kidney diseases: There is an increasing awareness of kidney
diseases and its complications. This is expected to drive the demand for
albumin & creatinine tests.
Challenges
Faced by the Albumin & Creatinine Tests Market
·
Pricing
Pressure: Due to the increasing
competition in the albumin & creatinine tests market, pricing pressures
have increased significantly. This has led to a decrease in the margins of the
suppliers, as they are forced to offer competitive prices to remain
competitive.
·
Regulatory Pressure: The albumin &
creatinine tests market is subject to a number of regulatory requirements in
order to ensure the accuracy and reliability of the tests. This has created an
additional burden for the suppliers, who must adhere to the complex and costly
regulatory requirements.
·
Technological
Advancements:
New technologies, such as computer-aided diagnosis and point-of-care testing,
are rapidly changing the albumin & creatinine tests market. These new
technologies are more efficient and cost-effective than traditional methods,
and as such, they are becoming increasingly popular. This has created a
challenge for the suppliers, who must remain up-to-date with the latest
developments in order to remain competitive.
·
Shortage
of Skilled Professionals:
Skilled and experienced professionals are necessary for the proper operations of
the albumin & creatinine tests market. However, due to the specialized
nature of the tests and their associated technologies,
Regional
Albumin & Creatinine Tests Market Analysis
The market is segmented
into North America, Europe, the Asia Pacific, Latin America and Middle East
& Africa. In 2019, North America accounted for the largest share of the
global albumin & creatinine tests market. The large share of this regional
segment can primarily be attributed to the growth in demand for rapid urine
tests, increasing prevalence of chronic conditions leading to various kidney
diseases, rising government initiatives, and growing geriatric population.
Major
Players in the Albumin & Creatinine Tests Market
The major players
operating in this ACR Tests Market are Thermo Fisher Scientific, Inc. (US),
Roche Diagnostics (Switzerland), PromoCell GmbH (Germany), Abbott Laboratories
(US), Siemens Healthineers (Germany), Danaher Corporation (US), Sysmex
Corporation (Japan), Ortho Clinical Diagnostics (US), Randox Laboratories (UK),
FUJIFILM Wako Pure Chemical Corporation (Japan), Abbexa Ltd. (UK), ACON
Laboratories, Inc. (US), Arbor Assays Inc. (US), ARKRAY Global Business Inc.
(Japan), Aviva Systems Biology (US), Axxora, LLC (UK), BioAssay Systems (US),
Nova Biomedical (US), Quantimetrix Corporation (US), RayBiotech Inc. (US),
Sekisui Diagnostics PEI Inc. (US), Teco Diagnostics (US), Tulip Diagnostics
(India), ulti med Products GmbH (Germany), and URIT Medical Electronic Co.,
Ltd. (China).
Recent
Developments and Trends in the Albumin & Creatinine Tests Market
·
In
2018, Danaher launched iQ Urinalysis Workcell.
·
In
2017, Abbott Laboratories acquired Alere to enter the overall urine analysis
market.
·
In
2020, Siemens Healthineers acquired Sysmex Corporation to enter the overall
urine analysis market.
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=156696568
Conclusion
The Albumin &
Creatinine Tests Market is expected to continue to grow over the forecast
period, driven by the increasing prevalence of chronic kidney diseases, the
growing geriatric population, and the rising demand for early diagnosis and
management of kidney diseases. The increasing availability of automated and
point-of-care testing systems, the rising prevalence of diabetes and hypertension,
and the growing awareness of patients regarding the early diagnosis and
management of kidney diseases are also projected to drive the growth of this
market.
